A novel PDE9 inhibitor WYQ-C36D ameliorates corticosterone-induced neurotoxicity and depression-like behaviors by cGMP-CREB-related signaling.
Xian-Feng HuangWen-Tao JiangLi LiuFang-Chen SongXia ZhuGui-Lan ShiShu-Ming DingHeng-Ming KeWei WangJames M O'DonnellHan-Ting ZhangHai-Bin LuoYi-Qian WanGuo-Qiang SongYing XuPublished in: CNS neuroscience & therapeutics (2018)
Our results show that inhibition of PDE9 by C36D produces antidepressant- and anxiolytic-like behavioral effects and memory enhancement by activating cGMP/PKG signaling pathway. PDE9 inhibitors may have the potential as a novel class of drug to treat MDD.
Keyphrases
- signaling pathway
- major depressive disorder
- nitric oxide
- drug induced
- protein kinase
- pi k akt
- depressive symptoms
- high glucose
- epithelial mesenchymal transition
- diabetic rats
- working memory
- mouse model
- bipolar disorder
- sleep quality
- emergency department
- physical activity
- climate change
- oxidative stress
- cell proliferation
- adverse drug
- electronic health record
- stress induced